Congestive Heart Failure

Congestive heart failure (CHF) is a clinical syndrome characterized by the inability of the heart to pump blood sufficiently to meet the metabolic demands of the body, leading to compensatory neurohormonal activation, fluid retention, and congestion. In veterinary medicine, CHF is typically classified as left-sided, right-sided, or biventricular, and is further categorized by the underlying cause (e.g., myopathic, valvular, or congenital). The syndrome is a common endpoint of various cardiac diseases, including chronic valvular disease (CVD) in dogs and hypertrophic cardiomyopathy (HCM) in cats. CHF is staged according to the International Small Animal Cardiac Health Council (ISACHC) or the American College of Veterinary Internal Medicine (ACVIM) staging system, which ranges from Stage A (high risk, no disease) to Stage D (refractory heart failure). The clinical manifestations arise from elevated ventricular filling pressures, leading to pulmonary edema (left-sided CHF) or ascites and pleural effusion (right-sided CHF).

The etiology of CHF is diverse and depends on the species and the underlying cardiac pathology. In dogs, the most common cause is chronic degenerative mitral valve disease (CVD), also known as myxomatous mitral valve degeneration, which leads to progressive mitral regurgitation and volume overload. Other causes include dilated cardiomyopathy (DCM), particularly in large-breed dogs such as Doberman Pinschers, Boxers, and Great Danes, often with a genetic basis. Arrhythmogenic right ventricular cardiomyopathy (ARVC) in Boxers and other breeds can also lead to right-sided CHF. In cats, hypertrophic cardiomyopathy (HCM) is the most prevalent, often with a genetic mutation in sarcomeric proteins. Restrictive cardiomyopathy (RCM), dilated cardiomyopathy (DCM), and unclassified cardiomyopathies are less common. Congenital defects, such as patent ductus arteriosus (PDA), ventricular septal defect (VSD), and aortic stenosis, can cause CHF in young animals. Additionally, acquired conditions like infective endocarditis, heartworm disease (Dirofilaria immitis), and chronic anemia can precipitate CHF. Toxic causes include doxorubicin-induced cardiomyopathy and nutritional deficiencies such as taurine deficiency in cats, which can lead to DCM. Systemic hypertension and hyperthyroidism in cats can exacerbate or cause cardiac remodeling and CHF.

CHF is a common clinical entity in small animal practice. In dogs, chronic valvular disease accounts for approximately 75% of all heart disease cases, with a higher prevalence in small-breed dogs such as Cavalier King Charles Spaniels, Dachshunds, and Poodles. The incidence increases with age, with most affected dogs being over 8 years old. DCM is more common in large-breed dogs, with certain breeds like Doberman Pinschers and Boxers having a genetic predisposition, and males may be overrepresented. In cats, HCM is the most common cardiac disease, with a prevalence of about 15% in the general feline population, and it is more common in middle-aged to older cats, with a male predisposition. Breeds such as Maine Coon and Ragdoll have known genetic mutations. Heartworm disease is endemic in regions with mosquito vectors, and the incidence of CHF due to heartworm has decreased with preventive measures but remains a concern in untreated animals. The epidemiology of CHF is influenced by geographic location, lifestyle, and owner compliance with preventive care.

The pathophysiology of CHF involves a complex interplay of hemodynamic, neurohormonal, and molecular mechanisms. Initially, cardiac injury or overload triggers compensatory mechanisms, including the Frank-Starling mechanism, myocardial hypertrophy, and activation of the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS). These compensatory responses initially maintain cardiac output but eventually become maladaptive, leading to progressive ventricular remodeling, fibrosis, and apoptosis. The activation of RAAS results in sodium and water retention, vasoconstriction, and increased preload, which exacerbates congestion. The SNS increases heart rate and contractility, but chronic activation leads to downregulation of beta-adrenergic receptors and myocardial toxicity. In left-sided CHF, elevated left atrial pressure is transmitted to the pulmonary veins, causing pulmonary capillary hydrostatic pressure to exceed plasma oncotic pressure, resulting in pulmonary edema. In right-sided CHF, elevated right atrial pressure leads to systemic venous congestion, causing hepatomegaly, ascites, and pleural effusion. The release of natriuretic peptides (ANP, BNP) is an early compensatory response, but their effects are overwhelmed in overt CHF. Additionally, inflammatory cytokines such as TNF-alpha and interleukins contribute to myocardial dysfunction and cachexia. The progression from asymptomatic cardiac disease to CHF is influenced by the severity of the underlying lesion, the rate of progression, and the adequacy of compensatory mechanisms.

Predisposing factors for CHF include species, breed, age, and genetic mutations. In dogs, small breeds with chronic valvular disease are predisposed, and the risk increases with age. Large breeds with DCM often have a genetic basis, and certain lines may be more affected. In cats, HCM is more common in males and in breeds like Maine Coon and Ragdoll. Other risk factors include obesity, which increases the workload on the heart, and systemic hypertension, which can exacerbate cardiac remodeling. Concurrent diseases such as chronic kidney disease, hyperthyroidism (in cats), and diabetes mellitus can complicate the management of CHF. Environmental factors such as high ambient temperature and stress can precipitate acute decompensation. Iatrogenic factors, such as overly aggressive fluid therapy, can induce CHF in animals with compromised cardiac function. Nutritional deficiencies, such as taurine deficiency in cats, can lead to DCM and CHF. Additionally, lack of regular veterinary care and poor owner compliance with preventive measures (e.g., heartworm prevention) increase the risk of developing CHF.

Clinical signs of CHF vary depending on the side of the heart affected and the chronicity. In left-sided CHF, the most common signs are tachypnea, dyspnea, cough (especially in dogs with mitral regurgitation), and exercise intolerance. On auscultation, a systolic murmur is often heard at the apex (mitral regurgitation) or base (aortic stenosis). Pulmonary crackles may be present due to pulmonary edema. In severe cases, respiratory distress with cyanosis may occur. Right-sided CHF is characterized by jugular venous distension, hepatomegaly, splenomegaly, ascites, and peripheral edema (less common in dogs and cats). Pleural effusion can cause tachypnea and dyspnea, particularly in cats. In both types, animals may show lethargy, anorexia, and weight loss. In acute CHF, animals may present with severe respiratory distress, collapse, or even cardiac arrest. Cats with HCM may show signs of thromboembolism, such as acute hindlimb paralysis, which is a severe complication. Early signs of CHF may be subtle, such as mild exercise intolerance or occasional cough, and may be mistaken for respiratory disease.

Differential diagnoses for CHF include primary respiratory diseases such as chronic bronchitis, tracheal collapse, pneumonia, and pulmonary neoplasia, which can present with cough and dyspnea. In cats, asthma and other lower airway diseases can mimic CHF. Pleural effusion due to other causes, such as feline infectious peritonitis (FIP), pyothorax, or chylothorax, should be considered. Ascites can be caused by hepatic disease, hypoproteinemia, or peritonitis. Other cardiac conditions that may not yet be in CHF, such as asymptomatic valvular disease or cardiomyopathy, should be differentiated. Systemic diseases like anemia, hyperthyroidism, and hypertension can cause similar signs. Additionally, neoplasia, such as heart base tumors or metastatic disease, can cause cardiac signs. A thorough diagnostic workup, including imaging and echocardiography, is essential to differentiate these conditions.

The diagnostic algorithm for CHF begins with a thorough history and physical examination, focusing on cardiac auscultation, respiratory rate and effort, and assessment of jugular veins and mucous membranes. If CHF is suspected, thoracic radiographs are the first-line imaging modality to evaluate cardiac size, pulmonary vasculature, and the presence of pulmonary edema or pleural effusion. Echocardiography is the gold standard for diagnosing the underlying cardiac disease and assessing chamber dimensions, wall thickness, and systolic and diastolic function. Electrocardiography (ECG) is useful to identify arrhythmias and chamber enlargement. Blood pressure measurement is important to rule out systemic hypertension. Baseline blood work, including complete blood count, serum biochemistry, and thyroid hormone levels (in cats), is recommended to identify concurrent diseases. Biomarkers such as NT-proBNP can help differentiate cardiac from non-cardiac causes of respiratory signs. In cases of suspected heartworm disease, antigen and antibody testing should be performed. If pericardial effusion is suspected, echocardiography is diagnostic. Advanced imaging such as cardiac MRI or CT may be indicated in select cases. The diagnostic algorithm should be tailored to the individual patient, but the above steps provide a systematic approach.

Laboratory findings in CHF are often nonspecific but can support the diagnosis and identify complications. Hematology may show stress leukogram or, in cases of chronic disease, anemia of inflammatory disease. Serum biochemistry may reveal elevated liver enzymes (ALT, ALP) due to hepatic congestion, and elevated renal parameters (BUN, creatinine) if renal perfusion is compromised. Electrolyte imbalances, such as hyponatremia and hyperkalemia, can occur due to RAAS activation and diuretic use. Blood gas analysis may show respiratory alkalosis in early pulmonary edema, progressing to hypoxemia and respiratory acidosis in severe cases. Urinalysis may show proteinuria or casts. Cardiac biomarkers, such as NT-proBNP, are elevated in CHF and can aid in diagnosis and prognosis. Troponin I may be elevated in cases of myocardial injury. In cats, serum T4 should be measured to rule out hyperthyroidism. In dogs, heartworm antigen testing is recommended. Additionally, assessment of renal function is crucial before initiating ACE inhibitors and diuretics.

Imaging plays a pivotal role in the diagnosis and management of CHF. Thoracic radiography is essential to evaluate cardiac size (vertebral heart score, VHS), pulmonary vasculature, and the presence of pulmonary edema or pleural effusion. In left-sided CHF, radiographs may show an enlarged left atrium, pulmonary venous congestion, and a diffuse interstitial to alveolar pattern in the caudodorsal lung fields. In right-sided CHF, hepatomegaly, ascites, and pleural effusion may be evident. Echocardiography is the cornerstone for diagnosing the underlying cardiac disease. It allows assessment of chamber dimensions, wall thickness, systolic function (ejection fraction, fractional shortening), diastolic function (mitral inflow velocities, tissue Doppler), and valvular morphology. In dogs with chronic valvular disease, echocardiography reveals thickened mitral valves and regurgitant jets. In cats with HCM, there is concentric left ventricular hypertrophy and often left atrial enlargement. Doppler echocardiography can quantify regurgitant flow and estimate pressures. Advanced imaging such as CT or MRI may be used for specific indications, such as evaluating for pulmonary thromboembolism or cardiac masses. In cases of pericardial effusion, echocardiography is diagnostic and can guide pericardiocentesis.

Cytology and histopathology are not routinely performed for the diagnosis of CHF, but they may be indicated in specific situations. If pleural effusion is present, thoracocentesis with fluid analysis can help differentiate a transudate (modified transudate) from an exudate or chylous effusion. In CHF, the fluid is typically a modified transudate with low cellularity and high protein content. Cytology may reveal mesothelial cells and occasional inflammatory cells. Histopathology of the myocardium may be obtained postmortem or via endomyocardial biopsy in rare cases. In dogs with DCM, histopathology shows myocyte degeneration, fibrosis, and attenuation of myofibers. In cats with HCM, there is myocyte hypertrophy, disarray, and interstitial fibrosis. These findings are not specific to CHF but reflect the underlying cardiomyopathy. In cases of myocarditis, histopathology may reveal inflammatory infiltrates. However, in clinical practice, the diagnosis of CHF is primarily based on imaging and clinical signs, and histopathology is rarely needed.

The treatment of CHF aims to alleviate clinical signs, improve quality of life, and slow disease progression. The mainstay of therapy includes diuretics, ACE inhibitors, and pimobendan. Furosemide is the most commonly used diuretic, administered at 1-2 mg/kg IV or SC for acute CHF, followed by oral dosing at 1-2 mg/kg q8-12h, titrated to the lowest effective dose. ACE inhibitors such as enalapril or benazepril are used at 0.5 mg/kg PO q12h to inhibit RAAS and reduce afterload. Pimobendan, a positive inotrope and vasodilator, is recommended at 0.25-0.3 mg/kg PO q12h for dogs with DCM or chronic valvular disease. In cats, pimobendan may be used at similar doses, but its efficacy is less established. Spironolactone, an aldosterone antagonist, may be added at 1-2 mg/kg PO q12h to reduce fibrosis and electrolyte imbalances. In acute CHF, oxygen supplementation, cage rest, and parenteral furosemide are essential. In cases of pleural effusion or ascites, therapeutic thoracocentesis or abdominocentesis may be performed. For refractory CHF, additional diuretics such as hydrochlorothiazide or torasemide may be considered. In cats with HCM, beta-blockers (atenolol) or diltiazem may be used to control heart rate and improve diastolic function. Management of underlying causes, such as heartworm disease or hyperthyroidism, is crucial. Dietary modification, including sodium restriction, is recommended. Regular monitoring of renal function and electrolytes is essential during therapy.

The prognosis for CHF varies depending on the underlying cause, stage, and response to therapy. In dogs with chronic valvular disease, the median survival time after the onset of CHF is approximately 6-12 months with appropriate therapy. Dogs with DCM have a median survival of 3-6 months, but pimobendan has been shown to improve survival. Cats with HCM and CHF have a median survival of 1-2 years, but this is highly variable. Negative prognostic indicators include severe clinical signs, poor response to initial therapy, presence of arrhythmias, and concurrent diseases. Serial monitoring of NT-proBNP and echocardiographic parameters can help assess prognosis. Animals that stabilize quickly and maintain a good quality of life may have a more favorable outcome. Owner compliance and regular veterinary follow-up are important for long-term management.

Follow-up for CHF patients is critical to monitor response to therapy and adjust medications. Initially, re-evaluation should occur within 1-2 weeks after diagnosis or after a change in therapy. At each visit, a physical examination, including body weight, heart rate, respiratory rate, and auscultation, should be performed. Thoracic radiographs may be repeated to assess pulmonary edema and cardiac size. Serum biochemistry and electrolytes should be monitored regularly, especially renal parameters and potassium levels, as diuretics and ACE inhibitors can cause azotemia and electrolyte imbalances. Blood pressure should be measured periodically. Echocardiography may be repeated every 6-12 months to assess disease progression. Owners should be educated to monitor resting respiratory rate at home; an increase above 30 breaths per minute may indicate worsening CHF. Adjustments to medication dosages should be made based on clinical signs and laboratory findings. Long-term management includes dietary sodium restriction, weight management, and regular exercise as tolerated. In cases of refractory CHF, referral to a veterinary cardiologist may be considered.

Pearls: 1) Always measure blood pressure in cats with suspected CHF, as systemic hypertension can exacerbate cardiac disease. 2) In dogs with chronic valvular disease, the onset of CHF is often preceded by an increase in resting respiratory rate; educate owners to monitor this. 3) Pimobendan has been shown to delay the onset of CHF in dogs with preclinical myxomatous mitral valve disease (EPIC trial). 4) In cats, taurine supplementation is not necessary for HCM but is crucial for DCM. 5) Furosemide should be titrated to the lowest effective dose to avoid azotemia. Pitfalls: 1) Do not use corticosteroids in animals with CHF, as they cause sodium and water retention. 2) Avoid overhydration with IV fluids in animals with cardiac disease. 3) Do not use ACE inhibitors in animals with acute renal failure or hyperkalemia. 4) In cats, stress during examination can precipitate acute CHF; handle gently and minimize stress. 5) Do not rely solely on radiographs to differentiate CHF from pneumonia; echocardiography and biomarkers are helpful.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are commonly used for CHF: Furosemide: Dogs and cats: 1-2 mg/kg IV, IM, SC, or PO q8-12h; for acute CHF, 2-4 mg/kg IV or IM, may repeat in 1-2 hours if needed. Oral maintenance: 1-2 mg/kg q8-12h, titrate to lowest effective dose. Enalapril: Dogs: 0.5 mg/kg PO q12h; Cats: 0.25-0.5 mg/kg PO q12h. Benazepril: Dogs and cats: 0.25-0.5 mg/kg PO q12h. Pimobendan: Dogs: 0.25-0.3 mg/kg PO q12h, given 1 hour before feeding; Cats: 0.25-0.3 mg/kg PO q12h (off-label). Spironolactone: Dogs: 1-2 mg/kg PO q12h; Cats: 1-2 mg/kg PO q12h. Hydrochlorothiazide: Dogs: 2-4 mg/kg PO q12h; Cats: 1-2 mg/kg PO q12h (used as adjunctive therapy). Torasemide: Dogs: 0.1-0.2 mg/kg PO q24h, may be used in refractory cases. Atenolol: Cats: 6.25-12.5 mg/cat PO q12h; Dogs: 0.25-1 mg/kg PO q12h. Diltiazem: Cats: 1-2 mg/kg PO q8h or 10 mg/cat q8h. Digoxin: Dogs: 0.005-0.01 mg/kg PO q12h (for atrial fibrillation or refractory CHF); Cats: 0.007 mg/kg PO q48h (use with caution). All dosages should be adjusted based on renal function and clinical response. Contraindications: ACE inhibitors should not be used in animals with hypotension, acute renal failure, or hyperkalemia. Pimobendan should not be used in animals with hypertrophic cardiomyopathy. Furosemide should be used with caution in animals with hepatic disease or electrolyte imbalances. Drug interactions: Concurrent use of ACE inhibitors and spironolactone may increase the risk of hyperkalemia. Furosemide may increase the toxicity of digoxin. Always monitor renal function and electrolytes during therapy.

Key clinical trials and consensus guidelines have shaped the management of CHF in veterinary medicine. The EPIC trial (2016) demonstrated that pimobendan delays the onset of CHF in dogs with preclinical myxomatous mitral valve disease. The QUEST study (2012) showed that pimobendan is superior to benazepril in dogs with CHF due to chronic valvular disease. The ACVIM consensus statement on the diagnosis and treatment of myxomatous mitral valve disease (2019) provides evidence-based recommendations. For feline HCM, the ACVIM consensus statement (2020) highlights the lack of evidence for specific therapies but recommends monitoring and managing comorbidities. The use of NT-proBNP as a diagnostic and prognostic biomarker is supported by multiple studies. The ISACHC guidelines for heart failure staging are widely used. Additionally, studies on the use of torasemide in dogs with refractory CHF have shown improved diuresis and quality of life. Overall, the evidence supports a multimodal approach with diuretics, ACE inhibitors, and pimobendan, tailored to the individual patient.